Oct. 28 at 10:40 PM
$IFRX $PFE $NVS crazy now there’s all of a sudden a bunch of interest in inflammation w
$B deals.
IL6 a different MOA / path - but are we finally getting attention on what inflammation does to organs - brain?
“Novartis is paying
$1.4 billion to acquire Tourmaline Bio and its sole drug, pacibekitug, an interleukin (IL)-6-targeted antibody for tackling inflammation leading to atherosclerotic cardiovascular disease. The repositioned IL-6 inhibitor, in-licensed from Pfizer, showed effects on a key biomarker and is set for phase 3 trials. Inflammation is known risk factor for cardiovascular disease, but current therapies mainly target high cholesterol.”
https://www.nature.com/articles/s41587-025-02885-5